Impact of Glasses for Vision Problems on Cognitive Function in Rural Older Adults
ConditionCognition Disorders
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60-79
SponsorYuju Wu
About this trial
The aim of this project is to explore whether vision correction can effectively slow cognitive decline in older adults.
The primary question it seeks to answer is: Can providing free near and/or distance vision correction glasses to older adults with refractive errors or uncorrected vision, who have normal baseline cognition and hearing, reduce the rate of cognitive decline over 36 months in a cost-effective manner? Researchers will compare the rate of cognitive decline over 36 months between older adults who receive refractive correction and those who do not.
Eligibility criteria
Qualifiers
Registered as a rural resident (holding rural household registration);
Age from 60 to 79 years at the time of enumeration;
Resident in the household for > = 3 months and planning to reside in the local area for the trial duration;
Distance vision impairment (VI, presenting visual acuity [VA] < 6/12 in the better-seeing eye and improving to ≥ 6/7.5 or better in either eye with spectacle correction) and/or near VI (presenting near VA < 6/12 at 40 cm when measured binocularly and improving to ≥ 6/7.5 or better in either eye with near correction);
Disqualifiers
Presence of glaucoma or visually significant cataract, or a history of surgical treatment for these or other major ocular conditions;
Consistent use of prescription spectacles and/or hearing aids;
Serious medical illness likely to result in loss to follow-up. Those less severely affected by conditions such as hypertension and/or diabetes will be eligible;
Failure on the whispered voice hearing screening test in the better ear (unable to repeat > = 3 out of 6 words whispered from behind the participant at a distance of 50 cm);
Trial design
Treatments tested in this trial
- Free Prescription Glasses
Treatment groups
964 Participants
are divided into 2 treatment groupsSponsors and collaborators
Yuju Wu
Lead sponsor
Sichuan University
Sponsor institution
Source ClinicalTrials.gov